Approximately 6 healthy male subjects will be administered a single 1500 mg intravenous dose
of 14C-GSK2251052 under fasted conditions. Blood, urine and fecal samples will be collected
for a minimum of 14 days following study drug administration. Safety and tolerability will be
monitored throughout the study. A follow-up visit will occur 7-14 days after study drug
administration.